Denali Therapeutics Inc. DNLI Business Segments — General and administration

Similar metrics at other companies

BAXMedical Products & Therapies — Selling, general and administrative expenses

$290M+1.4%

ABMTechnical Solutions — G&A

$20.8M+22.4%

VRTXPharmaceuticals — General and administrative expenses

$180.1M+16.0%

BLCOPharmaceuticals — Selling, general and administrative (Note 4)

$138M-9.8%

MANEReportable Segment — General and administrative, excluding personnel expenses

$4.61M+339%

ABTEstablished Pharmaceuticals — Selling, general, and administrative

$376M+7.1%

Questions, answered.

What is Denali Therapeutics Inc.'s business segments — general and administration?

Denali Therapeutics Inc. (DNLI) reported business segments — general and administration of $33.51M in Q1 2026.

How has Denali Therapeutics Inc.'s business segments — general and administration changed year-over-year?

Denali Therapeutics Inc.'s business segments — general and administration increased by 14.2% year-over-year, from $29.35M to $33.51M.

What is the long-term trend for Denali Therapeutics Inc.'s business segments — general and administration?

Over 3 years (2022 to 2025), Denali Therapeutics Inc.'s business segments — general and administration has grown at a 14.7% compound annual growth rate (CAGR), from $90.48M to $136.56M.

What does business segments — general and administration mean?

The total cost of all administrative and corporate support functions required to run the business. This metric provides a view of the company's fixed operating costs outside of direct research and development. It is a key indicator of the company's operational leverage and administrative efficiency.